Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
F&O
Financials
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Share Price History
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
About
Lupin Ltd.
NSE: LUPIN
|
BSE: 500257
|
ISIN: INE326A01037
|
Industry: Pharmaceuticals
US FDA Approval
|
Mid-range Performer
2104.1000
14.60
(
0.70
%)
NSE
Apr 24, 2025
15:31 PM
40.90% Gain from 52W Low
Volume:
1.6M
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Lupin Ltd.
09 Feb 2024
US FDA Approval
2104.10
0.70%
Lupin (HOLD): All-round beat; margins sustain raise to HOLD
Hold:
Lupin Ltd.
by
BOB Capital Markets Ltd.
Target: 1560
Recommendation
Target
BOB Capital Markets Ltd.
Strong Q3 with EBITDA/PAT of Rs 10.2bn/Rs 6.1bn, beating consensus by 17%/42%
Lupin Ltd. is trading above all available SMAs
More from Lupin Ltd.
Recommended
RARE Enterprises reduces holding in edible oils maker, Singhania cuts stakes in 2 firms to below 1%
Rakesh Jhunjhunwala and Associates |
24 Apr 2025, 05:45PM
Market closes lower, Tamilnad Mercantile Bank's Q4 profit grows 15.3% YoY to Rs 291.9 crore
Trendlyne Marketwatch |
24 Apr 2025, 03:55PM
Lupin expects normalization by September quarter
|
17 Apr 2020